2. The Anomaly

Morning arrived as a slow graying of the sky over Harlan Street. Clara had not slept. She had spent the hours before dawn cross-referencing the actuarial report with public financial disclosures, her laptop’s glow the only light in the apartment. By seven o’clock, she had three pages of notes and a name that had surfaced twice in the footnotes of the Trust’s investment portfolio: Victor Soren.

Soren was listed as a managing partner of Aegis Clinical Research Solutions. A separate search revealed that he had spent fifteen years as an executive at LuxBio, a pharmaceutical company that had settled a quiet lawsuit six years earlier over undisclosed adverse effects in a cognitive-enhancement drug trial. After leaving LuxBio, Soren had joined the board of trustees of the United Industrial Workers Pension Trust. He now chaired the investment committee.

Clara stared at the photograph accompanying a trade journal profile. Soren had the bland, confident face of a man who had never been denied anything. He was standing in front of a building she recognized: Blackmoor Penitentiary, its concrete walls rising behind him like a monument to institutional permanence. The caption read: Victor Soren, Managing Partner, Aegis Clinical Research Solutions, at the company’s operational headquarters in Borealis County.

She printed the photograph and pinned it to the corkboard above her desk, beside the actuarial report and the clipping about Elias Crane. Then she dressed in the same gray coat she had worn to the hearing and walked to the Avalon City Public Records Office.

The office occupied the basement of the old courthouse, a vaulted chamber of filing cabinets and microfiche readers that had somehow survived digitization. The clerk, a woman named Miriam who had known Clara since the days of Leo’s estate filings, waved her through without comment. Clara had come here often in the first year after Leo’s death, searching for property records, business licenses, anything that might explain the locked door and the gun and the improbable bullet trajectory. She had found nothing then. Today, she was looking for something far more specific.

The incorporation documents for Aegis Clinical Research Solutions were filed three and a half years earlier. The articles listed Victor Soren as the registered agent and sole director. The company’s stated purpose was “clinical research and pharmacological development.” Its initial capitalization was modest: two hundred thousand dollars from a shell entity called Borealis Investments Group, which Clara traced in turn to an address in the Dominion of Kirkwall, a small island nation with banking secrecy laws that rivaled those of the Caymans.

A second filing, dated six months after incorporation, showed a significant capital infusion: two million dollars from an entity called UIWPT Alternative Assets LP. Clara recognized the naming convention. It was a private investment vehicle wholly owned by the United Industrial Workers Pension Trust. The pension fund was not merely an investor in Aegis. It was the primary source of the company’s operating capital.

She requested every financial disclosure document associated with the Trust. Miriam brought her coffee and a stack of binders so thick it bent the metal shelf. Clara worked through lunch, ignoring the hunger that gnawed at her stomach, transcribing figures into her notebook. The Trust’s total investment in Aegis had grown from two million to just over twelve million dollars over three years. Each year’s disbursement was authorized by the investment committee, which Victor Soren chaired. The payments were classified not as direct investments but as “research partnership contributions,” which exempted them from the normal reporting requirements applied to standard asset purchases.

At two in the afternoon, Clara closed the last binder and sat back in her chair. The numbers were suggestive but not conclusive. She needed someone who could explain what kind of clinical research a pension fund might want to fund inside a maximum-security prison. She needed someone who had worked inside the actuarial machinery of the Trust.

She called Marcus Albright from a payphone in the courthouse lobby, a habit she had adopted after the first hang-up calls began two years ago. Marcus had been Leo’s protégé at the Trust, a young quantitative analyst who Leo had mentored and eventually recommended for the senior actuarial position. He had left the Trust eighteen months after Leo’s death, resigning without notice, and had since taken a job at a small consulting firm on the other side of Avalon City.

“Marcus Albright,” he answered on the fourth ring.

“It’s Clara Vance.”

A long pause. She heard the sound of a chair creaking, a door closing. When Marcus spoke again, his voice was lower. “Clara. I haven’t heard from you in almost a year.”

“I need to ask you about the Trust’s mortality assumptions,” she said. “Specifically, the collar adjustment that adds six years to the life expectancy of thirty-five-year-old factory workers.”

Another pause. This one stretched until she thought he had hung up.

“Where did you get that?” he asked finally.

“An arbitration hearing. Meridian Foods is contesting their withdrawal liability. The actuarial report was left on the table.”

“Left on the table.” Marcus’s tone was flat. “Of course it was. Clara, whatever you’re doing, you need to stop. You know what happened to Leo.”

“I know what they said happened. I’ve never believed it.” She gripped the payphone cord. “Marcus, I found an investment. The Trust has been funneling millions into a clinical research company that operates out of Blackmoor Penitentiary. The same prison where a death row inmate died yesterday, hours before his scheduled execution. The mortality tables used to assess withdrawal liability assume that younger workers will live implausibly long lives. Those two things are connected, and I think you know how.”

She heard him exhale, a long ragged breath. “Meet me at the Hornbeam Street footbridge,” he said. “Six o’clock. Alone.”

The line went dead.

The footbridge spanned the stagnant canal that cut through Avalon City’s old industrial quarter, a relic of a time when the city had been a center of textile manufacturing. By the time Clara arrived, the sun was setting behind the abandoned mills, painting the water in shades of rust and amber. Marcus was already there, leaning against the railing with his hands shoved deep into the pockets of an overcoat that was too thin for the weather.

He looked older than she remembered. The boyish energy that had defined him during his Trust years had been replaced by something hunted. His eyes flicked constantly, scanning the paths that led to the bridge.

“I can give you fifteen minutes,” he said. “Maybe less. They watch me.”

“Who watches you?”

“Who do you think?” He turned to face her, and she saw the fear etched into the lines around his mouth. “I left the Trust because I found out what the collar adjustment actually measured. It wasn’t based on standard actuarial tables. It was based on data.”

“What kind of data?”

“Biological data. Blood panels. Neurological assessments. Longevity projections derived from clinical trials. The Trust was told that this data came from voluntary participant surveys, but I started noticing anomalies. The improvement in life expectancy was concentrated in cohorts that matched the demographics of a very specific population: incarcerated men between the ages of thirty and fifty, housed in a single facility.”

“Blackmoor,” Clara said.

Marcus nodded. “I confronted Thorne about it. He told me the data was proprietary, that I didn’t have the security clearance to see the source files. A week later, my car was broken into. Nothing was taken, but the glovebox was open to a page I’d been working on—the very page where I had written the correlation between the mortality improvement and the Blackmoor inmate population. They wanted me to know they could reach me.” He looked at the darkening water. “I resigned the next day.”

Clara absorbed this. “What was Aegis actually doing inside the prison?”

“I don’t know exactly. But I overheard Soren on a phone call once, before I knew who he was. He was talking about a phase two trial. Something about telomere regeneration. He used a word I didn’t recognize: gerontological. I looked it up later. It means the study of aging.” Marcus shook his head. “They were running longevity trials on prisoners, Clara. They were testing drugs to extend human life, and the pension fund was betting on the results.”

“Betting how?”

“By adjusting the mortality assumptions. If the Trust could prove that its participants would live longer, it could justify higher withdrawal liability assessments from employers like Meridian Foods. Those assessments generated tens of millions in cash flow. Part of that cash flow was then reinvested into Aegis to fund further trials. It was a closed loop—an actuarial machine that fed on itself.” He met her eyes. “And Leo found it first.”

Clara felt the world tilt. “Leo knew?”

“Leo was the one who flagged the anomaly. He was an investment trustee, not an actuary, but he was smart. He saw the mortality numbers and knew they were wrong. He started asking questions. Six weeks later, he was dead.” Marcus looked over his shoulder again. “I have to go.”

“Wait.” She caught his arm. “Elias Crane died yesterday. He was forty-seven. The mortality table assumes men like him will live into their eighties. But he didn’t. Why?”

Marcus hesitated. “Not every subject responds to the treatment. Crane was probably a non-responder. Or he was given a control. They needed a baseline to compare against.” His voice was hollow. “He was sacrificed so the data would be clean.”

He pulled free and walked quickly toward the eastern end of the bridge. Clara watched him disappear into the gathering dusk. The canal water lapped against the stone embankment. Somewhere in the distance, a foghorn sounded from the river.

She drove back to Harlan Street, checking her rearview mirror every thirty seconds. No one followed her. The black sedan from the night before did not appear. She parked two blocks from her apartment and walked the rest of the way with her keys threaded between her fingers.

The apartment was as she had left it. The lock held. The deadbolt was drawn. She moved from room to room, checking closets and windows, and found nothing out of place. The actuarial report was still on the kitchen table. Her notes were still on the corkboard. She made herself a cup of tea and sat down at the desk, trying to process everything Marcus had told her.

A closed loop. An actuarial machine. Longevity trials on prisoners. And Leo, dead because he had asked the wrong questions.

Her gaze drifted to the closet where she kept Leo’s old belongings. She had boxed up his clothes two years ago, donated most of them, but she had kept a few items: his watch, his wedding ring, a leather briefcase that still smelled faintly of his cologne, and his old laptop. The laptop had been returned to her by the police after they concluded their investigation. She had tried to access it once, a few months after his death, but it had been password-protected, and she had not had the emotional stamina to guess. She had shoved it into the briefcase and left it there.

Now, three years later, she retrieved it.

The laptop was a heavy corporate-issue machine, scuffed at the corners. She plugged it into the charger and pressed the power button. The screen flickered. Then, unexpectedly, it lit up. The machine booted without prompting for a password. The desktop loaded—a generic background image of mountains, a few scattered folders. The date in the corner read the current date and time.

That was wrong. The laptop had been off for three years. It should have shown the date of Leo’s death. Someone had been inside it.

She opened the file explorer. The recent documents list was empty, but when she navigated to the root directory, she found a new folder that had not been there before. Its name was a string of numbers: 20260702.

She opened it. Inside was a single document: a PDF titled Mortality Portfolio – Phase Three Projections.

The document was dated six months after Leo’s death.

Her hands trembled as she scrolled. The file contained actuarial spreadsheets, clinical trial summaries, and financial projections for the Aegis partnership. The names of the subjects were replaced with alphanumeric codes, but the trial site was listed clearly: Blackmoor Penitentiary, Maximum Security Wing B. At the bottom of the document, a signature line bore the name Gregor Aldric, Chairman, UIWPT Investment Committee. And beside it, a second signature: Leo Vance, Lead Analyst.

Clara stared at the screen. Leo had signed this document. Leo had been listed as the lead analyst on a project that continued after his death. The signature was not forged—she knew her husband’s handwriting, the particular slant of his L, the way he looped his V. This was his signature, and it was dated six months after the police had told her he put a gun to his head and pulled the trigger.

She pushed back from the desk, her heart hammering. The laptop screen glowed in the darkened room, its cursor blinking steadily on Leo’s name.

Then, with no input from her, a new window opened on the desktop. A photograph filled the screen.

It showed Leo, alive, wearing a jacket she did not recognize, standing in front of a building she did not know. He was not smiling. He looked thinner than she remembered, and his eyes held an expression she had never seen on his face before—exhaustion, yes, but something else. Resignation. Or complicity. On either side of him stood two men: Victor Soren, whom she recognized from the trade journal photograph, and a third man, older, with silver hair and a face carved from stone. The photograph was taken in daylight. A timestamp in the corner read November 3, 2023.

Today’s date.

Clara stared at the photograph for a long time. Then she stood, walked to the kitchen, and poured herself a glass of whiskey from the bottle Leo had left in the cabinet three years ago. She drank it in one swallow and waited for her hands to steady.

They did not.

She returned to the desk and examined the photograph more closely. In the background, behind the three men, a sign was partially visible: ALDEN PSYCHIATRIC INSTITUTE, VISITOR ENTRANCE. She did not know the name. But she knew how to find it.

She opened a search engine. The cursor moved on its own, as if the laptop were possessed by a ghost, and typed: Alden Psychiatric Institute, patient directory. A page loaded. A login prompt appeared. A username and password were auto-filled from a saved credential file she had never seen before. The screen refreshed.

And there, at the top of the patient roster, was a single entry: Vance, Leo. Status: Active. Admitted: October 18, 2020. The day after his supposed death.

The laptop screen flickered once more, and then the document closed. The desktop returned to its mountain background. A single notification appeared in the corner: Remote session terminated.

Clara sat motionless in the dark, the whiskey glass empty in her hand, the photograph burned into her vision. Leo was alive. He had been alive for three years. And someone—someone who could control her laptop, who could enter her apartment without leaving a trace, who had been watching her since the moment she picked up the actuarial report at the hearing—had just given her the proof.

She did not know if it was a gift or a trap. She only knew that the next step led to Alden Psychiatric Institute, and that she would be there by morning.